Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.

Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies.
A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.
AuthorsSilvio Danese, Gionata Fiorino, Pierre Michetti
JournalJournal of Crohn's & colitis (J Crohns Colitis) Vol. 8 Issue 11 Pg. 1548-50 (Nov 2014) ISSN: 1876-4479 [Electronic] Netherlands
PMID25008477 (Publication Type: Journal Article)
CopyrightCopyright © 2014. Published by Elsevier B.V.
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Biosimilar Pharmaceuticals
  • Infliximab
  • Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
  • Antibodies, Monoclonal (therapeutic use)
  • Attitude of Health Personnel
  • Biosimilar Pharmaceuticals (therapeutic use)
  • Colitis, Ulcerative (drug therapy)
  • Crohn Disease (drug therapy)
  • Drug Approval
  • Drug Substitution
  • Europe
  • Gastroenterology
  • Health Care Surveys
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Infliximab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: